Three Capital Injections and a Guosen Securities Backing: Fengshi Technology's Krill Oil Bet on the Capital Markets

After the CSRC's official website announced that Guosen Securities would serve as the counseling institution and that Fengshi (Qingdao) Marine Technology Co., Ltd. had formally entered the listing counseling process, the domestic consumer health supplement sector, after several years of valuation correction, welcomed a highly representative IPO sample. This company, which uses Antarctic krill oil as its core selling point, went from a marketing-oriented trading firm by the shores of Jiaozhou Bay to an industry leader in just a few short years, and completed a dizzying series of equity evolutions and capital increases on the eve of this filing.

The Capital Sprint Rhythm of Three Capital Increases

Tracing the evolution of this newly minted IPO candidate through the underlying business registration records, its tightly paced capital sprint is clearly documented in Tianyancha archives. According to the Tianyancha App, Fengshi Technology was established in May 2018, with Gao Yicheng as its legal representative and registered capital of approximately 33.16 million yuan. At a key capitalization juncture, the company changed its name from "Fengshi (Qingdao) Marine Technology Co., Ltd." to a joint-stock company in July 2024, with registered capital raised from approximately 20.49 million yuan to 30 million yuan;

Subsequently, in August 2024, December 2024, and June 2026, the company increased its registered capital three more times in succession, finally settling at the current level of 33.16 million yuan.

This intensive path of equity expansion is the most standard "replenish capital, straighten the books, divide the pie" maneuver for an enterprise on the eve of reporting to regulators.

Under the current issuance and listing review rules, converting from a limited liability company to a joint-stock company is only the first step. The frequent capital increases that follow often carry two practical missions: on one hand, by bringing in external strategic investors or core employee shareholding platforms for capital injection, the company expands its net asset scale to meet the hard targets for listing net profit and net assets, while optimizing its cash flow reserves to cope with future expansion investments;

On the other hand, through dilution and fine-tuning of equity, it balances the shareholding structure among the founding team, strategic investors, and management, avoiding governance risks arising from overly concentrated or overly dispersed actual control.

The "Four-Way Split" Balanced Equity Structure

However, the shareholder list presented by Tianyancha reveals an extremely delicate balance of power.

Currently, the company is jointly held by shareholders including Qingdao Fengshi Dadao, ADATA Technology (Suzhou), Qingdao Fengshi Zhengyuan Partnership, and Qingdao Fengshi Mingyuan Partnership, among which the top four entities hold highly equal stakes, all locked at approximately 24.4%.

This rare "four-way split" balanced structure is a double-edged sword of immense tension in the eyes of the secondary market and the sponsor institution.

Among them, Gao Yicheng, through Fengshi Dadao and the two limited partnerships Zhengyuan and Mingyuan, effectively holds the vast majority of voting power in his hands, forming absolute control over the listing entity; while ADATA Technology's heavy anchor position directly opens a hidden passage between multinational capital and the supply chain. As the mainland industrial investment vehicle of global storage giant ADATA Group, ADATA not only brought abundant early-stage capital endorsement, but also, with its existing experience in overseas raw material procurement and precision biological extraction, provided an indispensable cloak of legitimacy for Fengshi's early product endorsements.

The Transformation Pressure as Krill Oil Sector Dividends Peak

The deeper driving force pushing Fengshi Technology to brave the deep waters of an IPO is the transformation pressure brought by the peaking of dividends in the krill oil and even high-end fish oil sector.

In past years, Antarctic krill oil, as a conceptual product rich in phospholipid-type Omega-3 and astaxanthin, waged a textbook-level consumer upgrade blitzkrieg on mainstream e-commerce platforms and short-video livestreams. Fengshi Technology precisely seized the anxiety of China's middle class over cardiovascular and cerebrovascular health, and through high-density ad buying, top livestreamer endorsements, and the "Antarctic original imported raw materials" label, quickly tore open a high-price-point gap in the traditional red ocean of fish oil, packaging it as a high-margin mega-hit product.

However, this model, which relies on internet traffic dividends to force-ripen, is inherently afflicted with the fatal flaws of extremely high sunk costs and an extremely shallow brand moat.

The "Chokepoint" Concerns of Raw Materials and Core Technology

The first is the "chokepoint" concern of raw materials and core technology. The vast majority of commercial fishing quotas for Antarctic krill are monopolized by a very small number of international giants such as Norway's Aker, and pricing power over upstream krill meal and crude oil is firmly in the hands of overseas fleets. Although Fengshi Technology vigorously emphasizes its own deep-processing and R&D capabilities in its marketing, it remains fundamentally and heavily dependent on the smoothness of overseas raw material supply.

Once geopolitical fluctuations occur or Antarctic ecological fishing limits tighten, a surge in raw material procurement costs will directly devour its proudly touted profit margins.

Expensive "Traffic Tax" and Compliance Red Lines

The second is the extremely expensive "traffic tax" and compliance red lines. In the domestic health supplement market, as major traditional pharmaceutical companies (such as Tongrentang and Baiyunshan) and multinational brands (such as Swisse) swarm in, the krill oil category has rapidly slid into a price war quagmire. To maintain its top online sales ranking, Fengshi Technology has had to continuously pay high traffic-buying fees and slot fees to platforms like Douyin and Tmall, keeping its sales expense ratio persistently high.

More critically, the "marine drug development" prominently listed in its business scope is undergoing a brutal dehydration period under serious regulatory scrutiny. For ordinary functional foods or health foods to leap to "marine innovative drugs" requires hundreds of millions in clinical R&D spending and a lengthy approval cycle. If the R&D expense ratio cannot support its "technology" label, its high-valuation logic will become extremely fragile under the microscope of IPO review.

The Pragmatic Signal Released by the Counseling Filing

This counseling filing in early autumn releases a pragmatic signal to the entire pan-health consumer sector: the first-generation consumer dividend of buying traffic to make mega-hit products and packaging new concepts to boost GMV has been exhausted. To obtain a golden ticket in a more stringent capital market, one must consolidate the lightweight OEM/private-label model into an industrial foundation with industrialized production capacity and an R&D moat.The counseling filing is only the first step of a long march. After tearing off the cloak of an internet-famous health supplement, whether Fengshi Technology is truly a new force in marine biopharmaceuticals with sustained造血 capabilities, or a large OEM ship forced to seek survival through listing by traffic costs, is a hard account that Gao Yicheng must thoroughly explain after Guosen Securities begins its counseling.